It is well known that thyroid disease is more frequent in women than in men; however, the molecular basis for this gender-based difference is still poorly understood. The activation of phosphoinositide 3-kinase (PI3K), through different mechanisms including loss of the PTEN tumor suppressor, is being increasingly recognized as a major player in the development of thyroid neoplastic lesions. Loss of Pten in the mouse thyroid results in a significant increase in the thyrocyte proliferative index, which is more prominent in the female mice. In this study, we show that 52% of the Pten À/À female mice, but only 12% of the males, develop follicular adenomas by 1 year of age. In addition, 50% of female mutants, but only 35% of males older than 1 year of age develop invasive, and often metastatic, follicular carcinomas. Mutant females have a significantly shorter overall survival compared with male mutants. Hormonal manipulation experiments established a direct role of estrogens in controlling the increased thyrocyte proliferation index in mutant females. Furthermore, while genetic ablation of one Cdkn1b allele accelerated the development of neoplastic lesions, it also abolished the gender differences in survival and reduced the difference in neoplastic lesion development rate, underlining a key role of p27 in mediating estrogen action in the thyroid follicular cells. These data, based on a clinically relevant model of thyroid follicular carcinoma, provide, to the best of our knowledge, for the first time in vivo evidence that circulating estrogens are directly responsible for the increased female susceptibility to thyroid disease, at least on activation of the PI3K pathway, and provide new insights into the gender-based differences characterizing thyroid neoplastic disorders.
Introduction
An extensive body of epidemiological data supports the idea that thyroid disorders, including nodular disease and thyroid carcinoma, are more frequent in women than in men (Libutti, 2005) . Several studies have attempted to link the pro-proliferative action of circulating estrogens on the thyroid epithelial cells to the increased prevalence of thyroid disease in females (Manole et al., 2001; Vivacqua et al., 2006; Chen et al., 2008; Kumar et al., 2010; Rajoria et al., 2010) . However, to date, solid evidence linking sex hormone action to thyroid pathogenesis in vivo is still lacking, also because of the limited number of model systems available to dissect these interactions in a physiologically relevant context.
The central role of the phosphoinositide 3-kinase (PI3K) signaling cascade in the pathogenesis of thyroid proliferative and neoplastic disorders has been recently corroborated by the development and analysis of a relevant mouse model (Yeager et al., 2007 (Yeager et al., , 2008 Miller et al., 2009) , as well as by solid clinicopathological data (Garcia-Rostan et al., 2005; Hou et al., 2007 Hou et al., , 2008 Vasko and Saji, 2007; Wang et al., 2007) .
Thyrocyte-specific deletion of the Pten tumor suppressor constitutively activates the PI3K signaling cascade, leading to hyperplastic thyroid glands at birth, and to the development of thyroid nodules and follicular adenomas by 6-8 months of age (Yeager et al., 2007) . One striking feature of the Pten mouse model of thyroid disease is the higher proliferative index of female mutant thyrocytes, compared with males, which leads to hypercellular female glands at a young age and to an increased incidence of thyroid adenomas in the females at 8 months of age (Yeager et al., 2007) .
While these data support a central role for the PI3K pathway in the regulation of thyroid proliferative homeostasis, they also suggest that its constitutive activation is not sufficient for full neoplastic transformation. In support of this idea, an oncogenic allele of Kras synergizes with Pten loss and leads to the rapid development of thyroid follicular carcinomas (Miller et al., 2009) .
In this study, the analysis of Pten mutant mice for up to 2 years not only reveals their high susceptibility to developing metastatic follicular carcinomas, but also sheds light on the molecular basis of the different thyrocyte proliferative index and risk of adenoma and carcinoma development between male and female mutant mice.
Results
We followed-up a total of 105 mutant mice for 2 years to determine the long-term consequences of constitutive PI3K activation in the thyroid follicular cells.
After 1 year of age, Pten mutant mice started showing signs of illness, and thyroid enlargement became macroscopically visible. At the end of the follow-up, we observed that the female mutants had a significantly reduced lifespan (mean survival: 73 weeks) compared with males (mean survival: 83 weeks) ( Figure 1a ). We also analyzed the thyroid pathological features of a large group of these mice (n ¼ 54) between 8 and 12 months of age to further expand and validate our previously published more limited series (Yeager et al., 2007) . We observed that, at this age, 52% of the females had developed thyroid follicular adenomas, compared with only 12% of the males (P ¼ 0.002) ( Figure 1b ). Remarkably, analysis of mice older than 1 year (n ¼ 34) revealed that 50% of the females, but only 35% of the males, had developed invasive and often metastatic thyroid follicular carcinomas (see below). When combined with the incidence of follicular adenomas, 93% of the females older than 1 year had developed neoplastic features, compared with only 65% of the males (P ¼ 0.05) ( Figure 1b ). These data establish the thyroid-specific Pten À/À strain as a physiologically and clinically relevant mouse model of follicular thyroid carcinoma. In addition, these mice represent a tool to further analyze the mechanisms responsible for the increased incidence of thyroid disorders in females.
We have previously reported that the levels of thyroid-stimulating hormone (TSH) and thyroxine hormones are virtually identical in young (3-month old) wild-type and mutant mice (Yeager et al., 2007) . In contrast, aging mutant mice displayed TSH suppression, in most cases to levels below the detection limit of our assay ( Figure 1c ). Conversely, thyroxine levels were slightly but significantly increased in all adenomabearing mice (Figure 1d , black dots). These data strongly suggest that the development of thyroid neoplasia in thyroid-specific Pten À/À mice is a cellautonomous event, independent of TSH stimulation.
Histopathological analysis of the organs from moribund mutant mice revealed the development of follicular thyroid carcinomas with local invasion into the fibrous capsule and into the adjacent muscles and vessels (Figure 2a ), as well as multiple lung metastases ( Figure 2b ). Neoplastic cells appeared generally well differentiated, although some areas displayed features compatible with poorly differentiated thyroid carcinomas (pleomorphic nuclei, prominent nucleoli and a higher proliferative index) ( Figures 2c and d) .
To characterize the effects of PI3K constitutive activation on the genes responsible for thyroid specification and function, we determined by quantitative real time PCR the expression levels of a battery of thyroidrelevant genes (Figure 3 ). Loss of Pten, as well as neoplastic transformation of Pten À/À thyrocytes, did not significantly or consistently change the expression of the three master genes involved in the specification and differentiation of the thyroid gland, namely Foxe1, Nkx2-1 and Pax8. Hyperplastic Pten À/À thyroids had normal mRNA levels of Tshr, Duox2 and Slc5a5 (sodium-iodide symporter), and slightly reduced expression of Tpo, Tg and Duox1. Interestingly, we observed that the expression of Tpo, Duox1 and Slc5a5 was significantly higher in the thyroids from female mice, irrespective of Pten status, suggesting a role for estrogen in the control of the expression of these genes. Carcinomas and, to a lesser extent, adenomas developing in Pten À/À mice showed an increase in the expression of Tshr, and a reduction of mRNA levels for Duox1, Duox2 and, notably, Slc5a5.
The differences in survival and neoplastic transformation rates between mutant males and females, as well as the differences in expression levels of Tpo, Duox1, and Slc5a5, prompted us to test the hypothesis that estrogen has a direct causal role in these gender-dependent effects. We first measured the mRNA expression of the three known estrogen receptors, ERa, ERb and Gpr30 in the thyroids from control and mutant mice. No significant differences were noted comparing males with females, and controls with mutants ( Figure 4a ). The expression of ERa was much higher than the other two receptors. Furthermore, ERa expression in isolated follicles was comparable with that in whole thyroids (data not shown), suggesting that ERa is the main estrogen receptor in the thyroid and that it is expressed by the follicular cells. Next, we ovariectomized a cohort of 4-week old control and Pten À/À immature mice (n ¼ 6) and then measured their thyrocyte proliferative index at 12 weeks of age by Ki-67 immunohistochemistry. Noticeably, complete estrogen ablation reduced the proliferative index of female thyroids to the same levels observed in mutant males (Figure 4b ). These data, to the best of our knowledge, provide for the first time in vivo evidence that circulating estrogens are directly responsible for the increased female susceptibility to thyroid disease, at least on activation of the PI3K pathway. We then performed the reverse experiment: 4-week-old male mutants (n ¼ 5 per group) were implanted subcutaneously with pellets for the continuous release of 17bestradiol (0.5 mg every 90 days) or control vehicle. After 8 weeks, thyrocyte proliferation was determined. Noticeably, estrogen treatment of mutant (but not control) males increased the thyrocyte proliferation index to the same levels observed in mutant females (Figure 4c ). These data provide further compelling support to the direct role of estrogen in the gender-specific proliferation differences observed in Pten À/À thyroids.
Using a candidate gene approach, we searched for differentially expressed genes that might mediate the estrogen-dependent proliferation increase in female mutants. The expression level of Cdkn1b (p27) was observed to be higher in the thyroid, but not in the liver (used as a Pten wild-type control), of Pten À/À male mice, compared with females ( Figure 5a ). Using Pten À/À mouse thyroid carcinoma cell lines (Miller et al., 2009) , we observed that estrogen could in fact repress the expression of p27 both at the mRNA and protein level (Figures 5b and c) , leading to the hypothesis that lower p27 levels in female mutants might be, at least in part, responsible for the increased thyrocyte proliferative index.
To test whether it is possible that the tumors developed by Pten À/À male mice spontaneously select for lower p27 expression levels, we measured p27 mRNA expression in a small series of aged male mutants (41 year of age) that had developed hyperplastic only or neoplastic lesions (Figure 5d ). Although the small size of the sample does not allow us to draw a final conclusion, the finding that, in two out of three tumors developed by male mutants, p27 expression was reduced to wild-type levels supports the idea that reduction in p27 level in the context of PI3K activation favors tumor development.
To genetically test this hypothesis, we crossed thyroidspecific Pten À/À mice to mice carrying a p27 null allele (Kiyokawa et al., 1996) . Not surprisingly, stepwise reduction of p27 gene dosage resulted in a progressive (Figure 5e ). Pten À/À ;p27 À/À mice had a mean survival of only 21 weeks, and all died by 6 months of age, with dramatically hyperplastic thyroids that caused dyspnea and prevented feeding. However, Pten À/À ;p27 þ /À mu-tants had a mean survival of 58 weeks, a 25% reduction compared with Pten À/À ;p27 þ / þ mice. Noticeably, the gender-based differences in survival observed in Pten À/À ; p27 þ / þ mice were totally rescued by the reduction of p27 gene dosage (Figure 5f ), suggesting that p27 is a relevant A new mouse model for thyroid follicular carcinoma VG Antico-Arciuch et al mediator of the effects of estrogen on thyroid tumor incidence. In fact, when we compared the proliferative index of thyroids from young, tumor-free Pten À/À ; p27 þ / þ and Pten À/À ;p27 þ /À mice, we observed that loss of one p27 allele in the males resulted in a larger proliferation increase than it did in the females (Figure 5g ). As a consequence, the gender differences in thyrocyte proliferation were drastically reduced in Pten À/À ;p27 þ /À mice. The Pten À/À ;p27 þ /À compound mutants survived long enough to develop adenomas and carcinomas; contrary to what we had observed in Pten À/À mice (Figure 1b) , the incidence of neoplastic lesions was not significantly different between Pten À/À ;p27 þ /À males and females, although a trend toward higher incidence in the latter was still detectable (Figure 5h ). These data strongly support a role for p27 as one important mediator of estrogen action in thyroid hyperproliferation and neoplastic transformation.
Discussion
Mouse models closely recapitulating both genetic and clinicopathological features of human carcinomas represent an invaluable tool to dissect the molecular pathways involved in the transformation process, as well as for preclinical studies aimed at validating new biomarkers and therapeutic approaches. Of the three cancer types originating from thyroid follicular cells, only papillary carcinoma has been effectively modeled in transgenic mice, either by overexpressing the RET-PTC fusion gene (Jhiang et al., 1996) or the BRAF V600E oncogenic allele (Knauf et al., 2005) . No genetically defined model of anaplastic thyroid cancer is available to date. Follicular carcinomas have been obtained in a small percentage of transgenic mice overexpressing the Nras Q61K allele (Vitagliano et al., 2006) and in 100% of mice carrying a mutation (PV) in the TRb receptor associated with thyroid hormone resistance (Suzuki al., 2002) . In both cases, and contrary to what is commonly observed in human patients, the genetic alteration increased TSH levels, making it difficult to separate the effects of the oncogenic alterations from those of constitutive Tshr stimulation. In fact, a compound mutant carrying the PV mutation together with a Tshr À/À allele did not develop carcinomas, further underlining the importance of uncoupling these two effects (Lu et al., 2010) .
Previously reported data from our group (Yeager et al., 2007) have provided the first in vivo evidence that constitutive PI3K activation confers thyroid follicular cells a proliferative advantage, leading to the development of hyperplasia and nodular lesions. In this study, we show that the vast majority of the hyperplastic lesions developing in thyroid-specific Pten À/À mice progress to aggressive, metastatic thyroid follicular carcinomas.
Two unique and extremely important features characterize this mouse model: first, the levels of TSH in mutant mice carrying pre-neoplastic lesions are within the normal range and then they decrease in older, tumor-bearing mice, thus eliminating the confounding effects of constitutive Tshr stimulation. Second, and most noticeably, this model recapitulates the genderbased differences in disease prevalence observed in human thyroid disorders.
The follicular carcinomas developing in the thyroidspecific Pten À/À model underline the insufficiency of constitutive PI3K signaling for neoplastic transformation: the 10-12 months necessary for invasive tumor development are clearly needed to accumulate additional genetic alterations. In fact, we have shown that an oncogenic Kras allele drastically reduces the time required for thyroid carcinoma development in the context of Pten loss (Miller et al., 2009 ). However, the extremely high incidence of invasive and metastatic carcinomas developing in aging thyroid-specific Pten À/À mice strongly supports a major role of the PI3K pathway in providing an optimal environment for the development of neoplastic lesions.
These tumors recapitulate several features of human aggressive follicular carcinomas: they invade through the capsule and into the vasculature, metastasize to the lungs, often display solid areas with enlarged, pleomorphic nuclei and a high proliferative index. Furthermore, as previously shown for human thyroid carcinomas, they consistently have reduced expression of Duox1 and Duox2 (Lacroix et al., 2001) and, more importantly, suppression of sodium-iodide symporter expression (Sodre et al., 2008) . The latter feature is particularly clinically relevant, as this mouse model can now be used to test approaches aimed at increasing sodium-iodide symporter expression in radioiodinerefractory thyroid carcinomas.
A unique and unexpected feature of this model is the increased tumor incidence in female mutants, mirroring the increased susceptibility of women to thyroid disorders. A role for estrogen in thyroid proliferation has been proposed by several groups, based on the analysis of the effects of estradiol on thyroid carcinoma cells in culture (Manole et al., 2001; Vivacqua et al., 2006; Chen et al., 2008; Kumar et al., 2010; Rajoria et al., 2010) . In this study, to the best of our knowledge, for the first time, our hormone manipulation experiments have provided in vivo evidence that, in the context of PI3K activation, circulating estrogens increase thyroid follicular cells proliferation. It is tempting to suggest that the relatively mild effect of estrogens on thyroid cells is uncovered and amplified by oncogenic events lowering the thyrocyte proliferation threshold. Further studies are needed to validate this hypothesis in the context of different oncogenic mutations. An additional new finding is the increased expression level of Tpo, Duox1 and Slc5a5 genes in female mice irrespective of their genotype, strongly suggesting that estrogen has a significant role in their transcriptional regulation.
Finally, we have provided in vivo evidence that the gender-based differences in thyrocyte proliferation and neoplastic transformation elicited by estrogens are due, at least in part, to the ability of these hormones to regulate p27 levels through mechanisms that include transcriptional regulation in addition to the known effects of estrogens on p27 protein degradation through Skp2 (Foster et al., 2003) .
In conclusion, our study validates the thyroid-specific Pten À/À mouse as a clinically relevant model of advanced and aggressive follicular carcinomas, uniquely recapitulating several features of human thyroid cancer. In addition, it provides evidence that ERa activation contributes to the increased susceptibility of females to thyroid proliferative disorders and neoplastic transformation, at least in part, through the control of p27 levels.
Materials and methods

Animals and treatments
The Pten L/L and TPO-Cre strains have been described (Yeager et al., 2007) . All strains were backcrossed in the 129Sv background for at least eight generations. Ovariectomy was performed on 4-week-old mice under Isoflurane anesthesia. The 4-week-old male mutants were implanted subcutaneously with pellets (Innovative Res, Sarasota, FL, USA) for the continuous release of E2 (0.5 mg every 90 days) or control vehicle.
Hormone measurements
Blood was collected by cardiac puncture. Serum TSH was measured using a sensitive, heterologous, disequilibrium double-antibody precipitation radioimmunoassay (Pohlenz et al., 1999) , and results were expressed in mU/l. All samples were individually analyzed for each mouse. Total thyroxine concentrations were measured by a solid-phase radioimmunoassay (Coat-a-Count; Diagnostic Products, Los Angeles, CA, USA) adapted for mice. Values of the respective limits of assays sensitivities were assigned to samples with undetectable TSH and thyroxine concentration.
Proliferation analysis
Ki-67-stained thyroid sections were photographed at Â 400 magnification and analyzed using the ImageJ software. Between 1500 and 3000 cells per slide were analyzed.
Cells and treatments
Several independent cell lines established from primary thyroid tumors developed by Pten mutant mice (Miller et al., 2009) were grown in phenol red-free Dulbecco's modified Eagle's medium with 10% charcoal-stripped fetal bovine serum. Estradiol (Sigma, St Louis, MO, USA) was added 24 h after plating. At the indicated time points, cells were collected in RIPA buffer for protein analysis and in TRIzol (Invitrogen, Carlsbad, CA, USA) for RNA analysis.
Western blot analysis
Thyroids and cells were homogenized on ice in RIPA buffer supplemented with Complete protease inhibitor tablet (Roche Diagnostics, Indianapolis, IN, USA). Western blot analysis was carried out on 20-40 mg proteins with a p27-specific antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and a b-tubulin antibody from Sigma-Aldrich.
Real time PCR
Total RNA was extracted with TRIzol and reverse transcribed using the Thermoscript kit (Invitrogen). Quantitative RT-PCR was performed on a StepOne Plus apparatus using the Absolute Blue qPCR Rox Mix (Thermo Scientific, Waltham, MA, USA) and TaqMan expression assays (Applied Biosystems, Carlsbad, CA, USA). Each sample was run in triplicate and GusB was used to control for input RNA. Data analysis was based on the C t method, and experiments were repeated at least three times using at least two independent organ pools (at least five mice per pool).
Statistical analysis
Experiments were performed at least three times. Data were analysed using the JMP 5.1 and Prism software packages. Differences with P-values o0.05 were considered statistically significant.
